Abstract
Abstract Background: Cytochrome P450 2E1 (CYP2E1), an ethanol-inducible enzyme, has been shown to metabolically activate various carcinogens, which is critical for the development of cancers. It has demonstrated that CYP2E1 polymorphisms alter the transcriptional activity of the gene. However, studies on the association between CYP2E1 PstI polymorphism and non-small cell lung cancer have reported conflicting results. Thus, the gain of the present study was to investigate whether CYP2E1 PstI polymorphism is associated with the development of non-small cell lung cancer in Chinese population. Method: A case-control study was conducted in which CYP2E1 PstI polymorphism was analyzed in 526 Chinese patients with non-small cell lung cancer and 526 age-matched healthy controls by PCR-RFLP. Odds ratios were estimated by multivariate logistic regression. Result: For CYP2E1 PstI polymorphism, C allele carriers (OR=0.67; CI=0.51-0.87; P=0.002) was associated with a decreased risk of non-small cell lung cancer when compared with GG homozygotes. In the group analyses by pathological types, for lung SCC and other types the ORs of the C allele carriers were (OR=0.60; CI=0.41-0.88; P=0.009) and (OR=0.54; CI=0.30-0.99; P=0.045), respectively. In the group analyses by smoking status, there was a significant association among nonsmokers (OR=0.57; CI=0.40-0.81; P=0.002), but not smokers. In the group analyses by TNM stage, there was no significance between CYP2E1 PstI polymorphism and the grade of non-small cell lung cancer. Conclusion: CYP2E1 PstI polymorphism is associated with decreased risk of development of non-small cell lung cancer and lung SCC or other types in Chinese patients. Key Words: lung cancer; CYP2E1; gene polymorphism; susceptibility; genetic variant Citation Format: Lei Cao, Jia Lin, Bing He, Hongge Wang, Juan Rao, Yingwen Liu, Xuemei Zhang. A regulatory variant in CYP2E1 affects the risk of lung squamous cell carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3252. doi:10.1158/1538-7445.AM2014-3252
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
